TriLink BioTechnologies (TriLink), has entered into an agreement with Nacalai USA, Inc., a San Diego based manufacturing and marketing company, for the distribution of TriLink’s modified nucleic acid products in Japan, Singapore, South Korea and Taiwan.

“With TriLink’s unique high quality product offering and Nacalai’s key role as a bridge to bringing new technologies to the Japanese research market, we feel that we can now have yet another opportunity to advance science. We are excited to join forces with the great team at Nacalai USA,” stated TriLink CEO, Richard Hogrefe, Ph.D.

“We are excited about the opportunity to introduce TriLink’s cutting-edge technology to the Japanese scientific research community. We believe TriLink’s unique CleanAmp products will bring us a new business in the Japanese market,” commented Toshi Ono, VP and COO at Nacalai USA.

The agreement will provide researchers in the Asian market access to high quality, modified nucleic acid products to further advance research efforts in areas such as molecular biology and proteomics.

TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research.

Nacalai USA, a wholly-owned subsidiary of Nacalai Tesque, Inc., Kyoto Japan., was founded in January 2005 in San Diego, California to bridge between the United States and Japan in the scientific research community.